Catalist-listed QT Vascular specializes in making coronary products, but has been struggling with poor financial health - recording losses over the past few years.
Its market cap has also been beaten down by shareholders - from a high of over 50 cents near the start of its IPO in 2014 to languishing to around less than 2 cents now.
But you might have seen it in the news lately, it was involved in a $28 million deal with Medtronics, one of the largest medical devices companies.
Co-founder and CEO Dr Eitan Konstantino chats with Ryan Huang and explains his plan to get the company back into the pink of health.